Circulating immune cell profile in patients with acromegaly: results from the PROMISE, a prospective clinical trial
Authors' conclusion
This is the first evidence of a distinct immunological pattern in ACRO that is independent of glucose metabolism. The immune signature may contribute to the persistence of cardio-metabolic and oncological risk observed in ACRO, even when the disease is adequately controlled by medical treatment.
Study context
- Population
- Consecutive outpatients with acromegaly (34 males, mean age 54.7 ± 15), July 2020–December 2024; controls with no significant differences in age or sex
- Participants
- 60 / 40 / 40
- Exposure
- Acromegaly vs healthy controls and vs T2D
- Acromegaly (ACRO)n = 60
- Controls (CTRL)n = 40reference
- T2DMn = 40
- Outcome
- Circulating immune cell (peripheral blood mononuclear cell (PBMC)) subpopulations
Methodological detailssingle-site, 8-week follow-up
- Single-site
- 8-week follow-up
Main finding
As reported in the abstract
- ACRO vs CTRL: lower total monocytes, decreased % classical and increased proportion of non-classical subsets
- ACRO vs CTRL: fewer NK cells, higher CD56dim and lower CD56bright subpopulations; similar T and B lymphocytes
- ACRO vs T2DM: lower total monocytes, higher classical and lower non-classical subsets, lower NK cells and B lymphocytes
Observational data: associations, not effects.
Further findings
Effect of treatment introduction or changes on immune profile · 8 weeks
- Short-term treatment appeared unable to restore immune cell profile but partially affected distributions of innate immune cell subpopulations
Original publication
Circulating immune cell profile in patients with acromegaly: results from the PROMISE, a prospective clinical trial. Eur J Endocrinol. Published 9 May 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →